A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
Information source: Hoffmann-La Roche
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Psoriasis
Intervention: calcipotriol hydrate [Daivonex] (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Hoffmann-La Roche Official(s) and/or principal investigator(s): Clinical Trials, Study Director, Affiliation: Hoffmann-La Roche
Summary
This single arm study will evaluate the efficacy and safety of sequential treatment with
Diavobet (betamethasone propionate 0. 5mg/g plus calcipotriol hydrate 50 micrograms/g) once
daily for 4 weeks followed by Daivonex (calcipotriol hydrate 50 micrograms/g) twice daily
for 4 weeks, in the control of signs and symptoms in patients with mild to moderate
psoriasis. Only patients showing a >50% response to Daivobet will progress to the Daivonex
maintenance phase. The anticipated time on study treatment is <3 months, and the target
sample size is 100-500 individuals.
Clinical Details
Official title: An Open Label Study to Evaluate the Clinical Response to Sequential Treatment With Daivobet and Daivonex in Patients With Mild to Moderate Psoriasis
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: PASI reduction
Secondary outcome: AEs.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- adult patients >=18 years of age;
- clinical diagnosis of psoriasis vulgaris;
- PASI score 1-12 in >=1 body area.
Exclusion Criteria:
- clinical presentation of erythrodermic pustular psoriasis, expressed in plates and
localized lesions on face and/or scalp;
- viral, fungal or bacterial skin infections;
- use of any topical treatment for psoriasis within previous 15 days;
- use of any systemic therapy and phototherapy for psoriasis within previous 30 days.
Locations and Contacts
Belem 66087-670, Brazil
Belo Horizonte 30150-221, Brazil
Botucatu 18618-000, Brazil
Brasilia 70840-901, Brazil
Campinas 13060-803, Brazil
Curitiba 8000001003, Brazil
Rio de Janeiro 20020-020, Brazil
Rio de Janeiro 22470-220, Brazil
Salvador 41110-170, Brazil
Sao Paulo 05403-900, Brazil
Additional Information
Starting date: February 2007
Last updated: August 17, 2015
|